"This evidence strengthens the relevance of the findings by Pietrobono et al., shedding light on the potential application of SMO inhibitors in concert with BRD4 inhibitors." BUFFALO, NY- July 19, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on May 26, 2023, entitled, " Combined targeting of HEDGEHOG signaling and BRD4 as a novel therapeutic option against melanoma ." The Hedgehog-GLI (HH/GLI) pathway is aberrantly activated in several types of cancer. Canonical HH/ GLI pathway is triggered by binding of HH ligands to the twelve-pass transmembrane receptor Patched 1 (PTCH1), which retrieves its inhibition on the seven-pass transmembrane G protein-coupled receptor Smoothened (SMO), leading to the activation of the GLI transcription factors.

https://www.miragenews.com/novel-strategy-dual-targeting-of-hedgehog-1050097/

#miragenews